Markets

Insider Trading

Hedge Funds

Retirement

Opinion

12 Best Medical Stocks to Buy Now

Page 1 of 11

In this article, we will look at the 12 Best Medical Stocks to Buy Now.

On September 26, Geoff Meacham, Managing Director of Citi Research, appeared on CNBC’s “Closing Bell Overtime” to talk about President Trump’s plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the United States.

President Trump recently announced the imposition of 100% tariffs on pharmaceutical products entering the US starting October 1st, unless they are building domestic manufacturing plants. The EU and Japan would be exempt from the 100% tariff, honoring the 15% cap that was put into place under the current trade deals.

READ ALSO: 11 Best Large Cap Value Stocks to Buy Now and 12 Best Strong Buy Stocks to Invest in According to Wall Street

Talking about this scenario, Meacham stated that the news could be a relief for investors who have been feeling uncertain about the sector since the initial tariff announcement on April 2nd. While he admitted that this isn’t the best case scenario for the companies, it certainly is a “bit of a derisking event”, according to him.

He added that many pharma companies have already made US investment promises, and he would be surprised if many companies haven’t already built new plants here or expanded their existing ones.

With these trends in view, let’s look at the best medical stocks to buy now.

Our Methodology

We used stock screeners to make a list of the best medical stocks and then selected the top 12 with the highest number of hedge fund holders as of Q2 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund holders.

Note: All data was sourced on September 30.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

12 Best Medical Stocks to Buy Now

12. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 71

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical stocks to buy now. RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences, Inc. (NASDAQ:GILD) on September 29 and set a price target of $98.00.

Gilead Sciences, Inc. (NASDAQ:GILD) reported a 2% growth in its total revenues for fiscal Q2 2025 to $7.1 billion compared to the same period last year, with management attributing the growth to higher HIV, Livdelzi, and Trodelvy sales.

Diluted EPS for the quarter reached $1.56 compared to $1.29 in the prior year period, with the increase primarily driven by net unrealized gains on securities compared to net unrealized losses in 2024 and higher product sales.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

11. HCA Healthcare, Inc. (NYSE:HCA)

Number of Hedge Fund Holders: 73

HCA Healthcare, Inc. (NYSE:HCA) is one of the best medical stocks to buy now. In a report released on September 26, Sarah James from Cantor Fitzgerald reiterated a Buy rating on HCA Healthcare, Inc. (NYSE:HCA) and set a price target of $444.00.

HCA Healthcare, Inc. (NYSE:HCA) reported a 6.4% growth in its revenues for fiscal Q2 2025 to $18.605 billion, while net income attributable to the company rose 13.1% to $1.653 billion.

Management further reported that diluted EPS rose 23.5% to $6.83 per diluted share, while diluted EPS, as adjusted, grew 24.4% to $6.84 per diluted share. Adjusted EBITDA also rose 8.4% to $3.849 billion.

HCA Healthcare, Inc. (NYSE:HCA) is a health care services company involved in the operation of hospitals, urgent care facilities, freestanding surgery centers and emergency care facilities, diagnostic and imaging centers, walk-in clinics, radiation and oncology therapy centers, and more.

Page 1 of 11

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!